Back to News
Market Impact: 0.2
Nurix Initiates Phase 1b/2 Bexobrutideg Trial In Lymphocytic Leukemia
Source: Nasdaq
Healthcare & Biotech
Nurix Therapeutics announced enrollment of the first patient in a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. This is an early clinical-development milestone; the article provides no efficacy results or other study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
NRIX0.55
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- Healthcare Services Group acquires NEXDINE Hospitality for $93.5M